Two Positive Nodes Represent a Significant Cut-off Value for Cancer Specific Survival in Patients with Node Positive Prostate Cancer. A New Proposal Based on a Two-Institution Experience on 703 Consecutive N+ Patients Treated with Radical Prostatectomy, Extended Pelvic Lymph Node Dissection and Adjuvant Therapy

European Urology

Volumn 55, Issue 2, 2009, Pages 261-270

  Briganti, Alberto ^a   Karnes, Jeffrey R ^b   Da Pozzo, Luigi Filippo ^a   Cozzarini, Cesare ^a   Gallina, Andrea ^a   Suardi, Nazareno ^a   Bianchi, Marco ^a   Freschi, Massimo ^a   Doglioni, Claudio ^a   Fazio, Ferruccio ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a   Blute, Michael L ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Lymph node metastasis; Number of positive nodes; Prostate cancer; Radical prostatectomy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HORMONAL THERAPY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS;

EID: 57649178941     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.09.043     Document Type: Article

References (26)

1. Heidehreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
2. Freedland D.J., Partin A.W., Humphreys E.B., et al. Radical prostatectomy for clinical stage T3 disease. Cancer 109 (2007) 1273-1278
3. Yossepowitch O., Eggener S.E., Serio A.M., et al. Secondary therapy, metastatic progression and cancer specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 53 (2008) 950-959
4. Gontero P., Marchioro G., Pisani R., et al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol 51 (2007) 922-930
5. Morgan W.R., Bergstralh E.J., and Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 41 (1993) 113-120
6. Van den Ouden D., Davidson P.J., et al. Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J Urol 151 (1994) 646-651
7. Gerber G.S., Thisted R.A., Chodak G.W., et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 32 (1997) 385-390
8. Hsu C.-Y., Joniau S., Oyen R., Roskams T., and Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 51 (2007) 121-129
9. Briganti A., Chun F.K.-H., Salonia A., et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49 (2006) 1019-1027
10. Bader P., Burkhard F.C., Markwalder R., et al. Is a limited lymph node dissection an adequate staging procedure for prostate cancer?. J Urol 168 (2002) 514-518
11. Heidenreich A., Ohlmann C.H., and Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52 (2007) 29-37
12. Heidenreich A., Varga Z., and Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167 (2002) 1681-1686
13. Allaf M.E., Palapattu G.S., Trock B.J., et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 172 (2004) 1840-1844
14. Cheng L., Zincke H., Blute M.L., et al. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91 (2001) 66-73
15. Palapattu G.S., Allaf M.E., Trock B.J., et al. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol 172 (2004) 1860-1864
16. Bader P., Burkhard F.C., Markwalder R., et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J Urol 169 (2003) 849-854
17. Daneshmand S., Quek M.L., Stein J.P., et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172 (2004) 2252-2255
18. Boorjian S.A., Thompson R.H., Siddiqui S., et al. Long-Term Outcome After Radical Prostatectomy for Patients With Lymph Node Positive Prostate Cancer in the Prostate Specific Antigen Era. J Urol 178 (2007) 864-871
19. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). American Joint Committee on Cancer Staging Manual. 6th ed (2002), Springer, Philadelphia
20. Beahrs O.H., Henson D.E., Hutter R.V.P., and Kennedy B.J. American Joint Committee on Cancer staging manual. 4th edition (1992), J.B. Lippincott, Philadelphia pp. 181-3
21. Schumacher M.C., Burkhard F.C., Thalmann G.N., Fleischmann A., and Studer U.E. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54 (2008) 344-352
22. Kattan M.W. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95 (2003) 634-635
23. Catalona W.J., Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270 (1993) 948-954
24. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
25. Bochner B.H., Herr H.W., and Reuter V.E. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 166 (2001) 2295-2296
26. Berglund R.K., Sadetsky N., DuChane J., Carroll P.R., and Klein E.A. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. J Urol 177 (2007) 526-529